coin-img-ETHETH+2.28%coin-img-BTCBTC+0.97%coin-img-SOLSOL+3.92%coin-img-XRPXRP+0.50%coin-img-ZECZEC+13.92%coin-img-SYNTBSCSYNTBSC+0.00%coin-img-USDCUSDC+0.00%coin-img-NEARNEAR+21.53%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.97%coin-img-SOLSOL+3.92%coin-img-XRPXRP+0.50%coin-img-ZECZEC+13.92%coin-img-SYNTBSCSYNTBSC+0.00%coin-img-USDCUSDC+0.00%coin-img-NEARNEAR+21.53%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.97%coin-img-SOLSOL+3.92%coin-img-XRPXRP+0.50%coin-img-ZECZEC+13.92%coin-img-SYNTBSCSYNTBSC+0.00%coin-img-USDCUSDC+0.00%coin-img-NEARNEAR+21.53%coin-img-ETHETH+2.28%coin-img-BTCBTC+0.97%coin-img-SOLSOL+3.92%coin-img-XRPXRP+0.50%coin-img-ZECZEC+13.92%coin-img-SYNTBSCSYNTBSC+0.00%coin-img-USDCUSDC+0.00%coin-img-NEARNEAR+21.53%
user-avatar
The Times

NHS backs AstraZeneca breast cancer drug Enhertu for use in England after cost-effectiveness change

AI Market Summary
England's NHS approved AstraZeneca's Enhertu for metastatic breast cancer after a confidential price deal and an upward revision to NICE cost-effectiveness thresholds tied to a UK–US pharma partnership. The policy shift signals a more permissive reimbursement regime for high-cost innovative therapies, potentially improving UK market access for branded drugs. Broader market impact is limited, but it marginally reduces UK pricing and access uncertainty in biopharma.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.84%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The NHS has agreed to roll out AstraZeneca’s breast cancer drug Enhertu in England after years of disputes over its cost. The drug had previously been rejected in 2024 because it failed NICE’s cost-effectiveness criteria, but it will now be available from Thursday following a confidential price deal. The government also raised the NHS cost-effectiveness threshold in April, after President Donald Trump threatened a 100% tariff on pharmaceutical exports to the US unless the UK spent more on medicines.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Finance

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.